FusionNeoAntigen

FusionNeoAntigen identifies fusion gene-derived neoantigens and characterizes their sequences and HLA binding potential to support cancer immunotherapy research.

Key Features:

• Dedicated Neoantigen Resource: Focuses specifically on fusion gene-derived neoantigens relevant to cancer immunotherapy.
• Extensive Data Repository: Contains approximately 43,000 fusion proteins derived from around 16,000 in-frame fusion genes sourced from FusionGDB2.0.
• Neoantigen Prediction and Screening: Performs neoantigen prediction and virtual screening between fusion breakpoint peptides and human leukocyte antigens (HLAs).
• Comprehensive Fusion Gene Information: Includes corresponding protein sequences, fusion breakpoint peptide sequences, RNA and protein sequences relevant for vaccine development, and literature curation.
• Immunotherapy Development Support: Reports samples with fusion-specific neoantigens and potential CAR-T targetable cell-surface fusion proteins.
• Future Enhancements: Plans to report all potential fusion-specific neoantigens from approximately 120,000 human fusion genes across all possible open reading frames.

Scientific Applications:

• Personalized immunotherapy: Enables identification of patient-specific fusion-derived neoantigens for tailored T-cell or vaccine approaches.
• Vaccine design: Supplies fusion breakpoint peptide and RNA/protein sequence data to inform vaccine antigen selection.
• CAR-T target identification: Identifies potential cell-surface fusion proteins amenable to CAR-T targeting.
• Oncology and immunotherapy research: Supports discovery and characterization of fusion-driven immunogenic targets across cancer types.

Methodology:

Integrates FusionGDB2.0 to compile ~43,000 fusion proteins from ~16,000 in-frame fusion genes and applies neoantigen prediction algorithms and virtual screening of fusion breakpoint peptides against human leukocyte antigens (HLAs).